{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:14:40Z","timestamp":1764936880516},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T00:00:00Z","timestamp":1481846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Obesity"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Obesity is a significant risk factor for the development of endometrial hyperplasia and cancer. More conservative prevention and management strategies are attractive due to the increased surgical risk and complication rates associated with obesity. The Levonorgestrel\u2010releasing intrauterine system (<jats:styled-content style=\"fixed-case\">LNG\u2010IUS<\/jats:styled-content>, Mirena) has been shown to reduce the risk of developing endometrial cancer. The recent joint Green Top Guideline on the Management of Endometrial Hyperplasia published by the Royal College of Obstetricians and Gynaecologists (<jats:styled-content style=\"fixed-case\">RCOG<\/jats:styled-content>) with the British Society for Gynaecological Endoscopy (<jats:styled-content style=\"fixed-case\">BSGE<\/jats:styled-content>) recommends the <jats:styled-content style=\"fixed-case\">LNG\u2010IUS<\/jats:styled-content> for the medical management of endometrial hyperplasia without atypia. This case study reports on the development of endometrioid adenocarcinoma despite the presence of an <jats:styled-content style=\"fixed-case\">LNG\u2010IUS<\/jats:styled-content> following a negative hysteroscopy in a 56\u2010year\u2010old woman with morbid obesity. This report highlights the need for patients and clinicians to remain vigilant to the early warning signs of developing endometrial cancer, especially in those at an increased risk secondary to obesity.<\/jats:p>","DOI":"10.1111\/cob.12168","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T16:35:23Z","timestamp":1481992523000},"page":"54-57","source":"Crossref","is-referenced-by-count":10,"title":["Development of endometrioid adenocarcinoma despite Levonorgestrel\u2010releasing intrauterine system: a case report with discussion and review of the <scp>RCOG<\/scp>\/<scp>BSGE<\/scp> Guideline on the Management of Endometrial Hyperplasia"],"prefix":"10.1111","volume":"7","author":[{"given":"A. C. L.","family":"van der Meer","sequence":"first","affiliation":[{"name":"University Hospital Lewisham Lewisham and Greenwich NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. S.","family":"Hanna","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital Lewisham and Greenwich NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,12,16]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(83)90111-7"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2014.09.024"},{"key":"e_1_2_5_4_1","unstructured":"NCIN. Outline of Uterine Cancer in the United Kingdom: Incidence Mortality and Survival 2013."},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60892-8"},{"key":"e_1_2_5_6_1","unstructured":"Royal College of Obstetricians and Gynaecologists (RCOG). Endometrial Cancer in Obese Women. RCOG Scientific Impact Paper No. 32. London; May2012(cited 29 March 2016). URLhttps:\/\/www.rcog.org.uk\/en\/guidelines\u2010research\u2010services\/guidelines\/sip32\/"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.56.4.305"},{"key":"e_1_2_5_8_1","unstructured":"National Institute for Health and Care Excellence (NICE). Heavy Menstrual Bleeding: Assessment and Management. NICE Guideline CG44. London: National Institute for Health and Care Excellence;2007(cited 29 March 2016). URLhttps:\/\/www.nice.org.uk\/guidance\/cg44"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2007.11.011"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.05.042"},{"key":"e_1_2_5_11_1","unstructured":"Royal College of Obstetricians and Gynaecologists (RCOG) with the British Society for Gynaecological Endoscopy (BSGE). Management of Endometrial Hyperplasia. Green\u2010top Guideline No. 67. RCOG\/BSGE Joint Guideline. London;2016(cited 29 March 2016). URLhttps:\/\/www.rcog.org.uk\/en\/guidelines\u2010research\u2010services\/guidelines\/gtg67\/"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1982.tb01625.x"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.03.037"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31828cb563"},{"key":"e_1_2_5_15_1","article-title":"Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study","author":"Trimble CL","journal-title":"Cancer"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.03.048"},{"key":"e_1_2_5_17_1","first-page":"CD007245","article-title":"Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen","volume":"4","author":"Chin J","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_5_18_1","first-page":"492","article-title":"The role of levonorgestrel\u2010releasing intrauterine system for endometrial protection in women with breast cancer taking tamoxifen","volume":"35","author":"Shi Q","year":"2014","journal-title":"Eur J Gynaecol Oncol"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2014.06.014"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2002.6817"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1783\/147118906776276143"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00546.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmig.2008.08.016"}],"container-title":["Clinical Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcob.12168","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cob.12168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T08:06:35Z","timestamp":1696320395000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cob.12168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,16]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/cob.12168"],"URL":"https:\/\/doi.org\/10.1111\/cob.12168","archive":["Portico"],"relation":{},"ISSN":["1758-8103","1758-8111"],"issn-type":[{"value":"1758-8103","type":"print"},{"value":"1758-8111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,16]]}}}